CSPIA
EDIT icon

Cary Street Partners Investment Advisory’s Editas Medicine EDIT Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100
Closed -$780 – 930
2023
Q3 		$780 Hold
100
– – ﹤0.01% 1757
2023
Q2 		$823 Buy
+100
New +$871 ﹤0.01% 1665

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cary Street Partners Investment Advisory's EDIT Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 100 shares — an estimated $780 sold.

Cary Street Partners Investment Advisory first reported a position in EDIT in Q2 2023 and held it in 2 quarters. The position peaked at $823 in Q2 2023. 226 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 100 Editas Medicine shares in Q4 2023, an estimated $780.
  • Cary Street Partners Investment Advisory first reported a position in Editas Medicine in Q2 2023 and held it in 2 quarters.
  • Cary Street Partners Investment Advisory's Editas Medicine position peaked at $823 in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.